Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for kids with severe psoriasis: drug trial underway

NCT ID NCT04123795

Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 3 times

Summary

This study tests a drug called certolizumab pegol (Cimzia) in children aged 6 to 17 with moderate to severe plaque psoriasis. The goal is to see how the drug moves through the body and whether it is safe. Some children will get the drug, others a placebo. The study is active but no longer recruiting new participants.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
certolizumab pegol (Cimzia)
What this could lead to
If successful, this could provide a new treatment option for children with moderate to severe plaque psoriasis, helping to clear skin and reduce symptoms.
What could go wrong
This is a relatively small study (49 participants) focused on drug levels and safety, not yet proving effectiveness. As with any immune-suppressing drug, there are risks of serious infections and allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

49 people

The number who actually took part.

Started

Jan 2020

Finished

Jul 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Study participant must have a diagnosis of moderate to severe plaque psoriasis (PSO) for ≥3 months and: 1. Body Surface Area (BSA) affected by psoriasis ≥10 % 2. Physician's Global Assessment (PGA) score ≥3 (on a scale from 0 to 4) 3. Psoriasis Area and Severity Index (PASI) score is ≥12 or 4. PASI score is ≥10 and \<12 with at least one of the following: * \>Clinically relevant facial or scalp involvement * \>Clinically relevant genital involvement * \>Clinically relevant palm and sole involvement * \>Clinically relevant axillary involvement Study participants aged ≥12 years may alternatively have a diagnosis of moderate to severe mixed guttate/plaque PSO with \>50 % to \<80 % guttate lesions for ≥3 months, and must meet the same criteria listed above * Study participant must be a candidate for systemic psoriasis therapy and/or phototherapy and/or photochemotherapy Exclusion Criteria: * Study participant previously participated in this study or has previously been treated with certolizumab pegol (CZP) * Study participant has generalized pustular or erythrodermic psoriasis (PSO) * Study participant has guttate PSO without plaque PSO * Study participant has had a primary failure to an anti-tumor necrosis factor agent * Study participant has had prior exposure to \>2 biologic therapies * Study participant has a history of severe major depression or suicide attempt (including an actual attempt, interrupted attempt, or aborted attempt), or has had suicidal ideation in the past 6 months as indicated by a positive response ("Yes") to either Question 4 or Question 5 of the "Screening/Baseline" version of the Columbia Suicide Severity Rating Scale (CSSRS) at Screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mixed guttate/plaque psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mixed guttate/plaque psoriasis Moderate chronic plaque psoriasis Severe chronic plaque psoriasis

Contacts and locations

Locations

  • Ps0007 50156

    Arlington, Texas, 76011, United States

  • Ps0007 50161

    Los Angeles, California, 90045, United States

  • Ps0007 50162

    Fountain Valley, California, 92708, United States

  • Ps0007 50168

    Chicago, Illinois, 60611, United States

  • Ps0007 50169

    Jacksonville, Florida, 32256, United States

  • Ps0007 50175

    Phoenix, Arizona, 85006, United States

  • Ps0007 50183

    Calgary, Canada

  • Ps0007 50187

    Edmonton, Canada

  • Ps0007 50196

    Thousand Oaks, California, 91320, United States

  • Ps0007 50217

    Boca Raton, Florida, 33428, United States

  • Ps0007 50225

    Calgary, Canada

  • Ps0007 50230

    Rome, Georgia, 30161, United States

  • Ps0007 50232

    Detroit, Michigan, 48202, United States

  • Ps0007 50248

    Hialeah, Florida, 33016, United States

  • Ps0007 50265

    San Juan, Puerto Rico

  • Ps0007 50268

    Miami, Florida, 33155, United States

  • Ps0007 50269

    Wellington, Florida, 33449, United States

  • Ps0007 50277

    San Antonio, Texas, 78218, United States

  • Ps0007 50286

    Topeka, Kansas, 66614, United States